CD274 and colorectal carcinoma: Treatment of MSI-H/dMMR CRC targeting PD-1 or PD-L1 inhibition by FDA-approved ICIs, including atezolizumab, avelumab, pembrolizumab, and nivolumab, has been reported [35].